 | Up a level |
Janssen, J J W M; Löwenberg, B; Manz, M; Biemond, B J; Westerweel, P E; Klein, S K; Fehr, M; Sinnige, H A M; Efthymiou, A; Legdeur, M C J C; Pabst, T; Gregor, M; van der Poel, M W M; Deeren, D; Tick, L W; Jongen-Lavrencic, M; van Obbergh, F; Boersma, R S; de Weerdt, O; Chalandon, Y; ... (2022). Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome. Leukemia, 36(9), pp. 2189-2195. Nature Publishing Group 10.1038/s41375-022-01657-3
Peter, R; Müntener, C; Demuth, D; Heim, D; Stucki, F; Mevissen, Meike; Gerspach, C; Kaske, M; Steiner, Adrian; Meylan, Mireille; Bodmer, Michèle; Schüpbach-Regula, G.; Feldmann, M; Naegeli, H (2018). [AntibioticScout.ch: Decision support for the prudent use of antimicrobials: Application in cattle]. Schweizer Archiv für Tierheilkunde, 160(4), pp. 219-226. Gesellschaft Schweizer Tierärztinnen und Tierärzte 10.17236/sat00154
Hehlmann, R; Lauseker, M; Saußele, S; Pfirrmann, M; Krause, S; Kolb, H J; Neubauer, A; Hossfeld, D K; Nerl, C; Gratwohl, A; Baerlocher, Gabriela M.; Heim, D; Brümmendorf, T H; Fabarius, A; Haferlach, C; Schlegelberger, B; Müller, M C; Jeromin, S; Proetel, U; Kohlbrenner, K; ... (2017). Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia, 31(11), pp. 2398-2406. Nature Publishing Group 10.1038/leu.2017.253
Peter, R; Demuth, D; Müntener, C; Lampart, M; Heim, D; Mevissen, Meike; Schüpbach, Gertraud; Schuller, Simone; Stucki, F; Willi, B; Burkhardt, W; Francey, Thierry; Nett, C; Tschuor, F; Naegeli, H (2017). AntibioticScout.ch: Eine Entscheidungshilfe für den umsichtigen Einsatz von antimikrobiellen Wirkstoffen: Anwendung in der Kleintiermedizin. Schweizer Archiv für Tierheilkunde, 159(10), pp. 525-533. Huber 10.17236/sat00129
Miranda, M B; Lauseker, M; Kraus, M-P; Proetel, U; Hanfstein, B; Fabarius, A; Baerlocher, Gabriela M.; Heim, D; Hossfeld, D K; Kolb, H-J; Krause, S W; Nerl, C; Brümmendorf, T H; Verbeek, W; Fauser, A A; Prümmer, O; Neben, K; Hess, U; Mahlberg, R; Plöger, C; ... (2016). Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV. Leukemia, 30(6), pp. 1255-1262. Nature Publishing Group 10.1038/leu.2016.20
Eggimann, L; Girsberger, S; Halter, J; Gerull, S; Tichelli, A; Baldomero, H; Heim, D; Passweg, J; Rovó, Alicia (2015). Kinetics of peripheral blood chimerism for surveillance of patients with leukemia and chronic myeloid malignancies after reduced-intensity conditioning allogeneic hematopoietic SCT. Bone marrow transplantation, 50(5), pp. 743-745. Nature Publishing Group 10.1038/bmt.2015.3
Gotta, V; Widmer, N; Decosterd, L A; Chalandon, Y; Heim, D; Gregor, M; Benz, R; Leoncini-Franscini, L; Baerlocher, Gabriela M.; Duchosal, M A; Csajka, C; Buclin, T (2014). Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial. Cancer chemotherapy and pharmacology, 74(6), pp. 1307-1319. Springer 10.1007/s00280-014-2599-1
O'Meara, A; Pabst, T; Heim, D; Gerull, S; Bucher, C; Halter, J; Arber, C; Rovò, A; Tichelli, A; Gratwohl, A; Stern, M (2011). High-dose melphalan with or without stem cell support before myeloablative allo-SCT for remission induction in patients with advanced relapsed or refractory AML. Bone marrow transplantation, 46(5), pp. 636-40. London: Nature Publishing Group 10.1038/bmt.2010.181
Hasler, RM; Berov, S; Benneker, L; Dubler, S; Spycher, J; Heim, D; Zimmermann, H; Exadaktylos, AK (2010). Are there risk factors for snowboard injuries? A case-control multicentre study of 559 snowboarders. British journal of sports medicine, 44(11), pp. 816-21. London: BMJ Publishing Group 10.1136/bjsm.2010.071357
Taverna, C; Bargetzi, M; Betticher, D; Gmür, J; Gregor, M; Heim, D; Hess, U; Ketterer, N; Lerch, E; Matthes, T; Mey, U; Pabst, T; Renner, C (2010). Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations. Swiss medical weekly, 140, w13054. Muttenz: EMH Schweizerischer Ärzteverlag 10.4414/smw.2010.13054
Hasler, RM; Dubler, S; Benneker, LM; Berov, S; Spycher, J; Heim, D; Zimmermann, H; Exadaktylos, AK (2009). Are there risk factors in alpine skiing? A controlled multicentre survey of 1278 skiers. British journal of sports medicine, 43(13), pp. 1020-5. London: BMJ Publishing Group 10.1136/bjsm.2009.064741
Zenhäusern, R; Schmitz, S-F Hsu; Solenthaler, M; Heim, D; Meyer-Monard, S; Hess, U; Leoncini, L; Bargetzi, M; Rufener, B; Tobler, A (2009). Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98). Leukemia & lymphoma, 50(9), pp. 1501-11. London: Informa Healthcare 10.1080/10428190903131755
Gratwohl, A; Heim, D; Bargetzi, M; Baerlocher, GM; Chalandon, Y; Duchosal, M; Gregor, M; Hess, U; Oppliger Leibundgut, E; Passweg, J; Schranz, U; Dirnhofer, S (2007). Behandlung der chronischen myeloischen Leukämie 2007. Schweizerisches Medizin-Forum SMF / Swiss medical forum / Forum médical suisse FMS(7), pp. 934-940. Basel: EMH Editores Medicorum Helveticorum
Köfler, M; Seuberlich, Torsten; Maurer, E; Heim, D; Doherr, Marcus; Zurbriggen, Andreas; Botteron, Catherine (2006). TSE surveillance in small ruminants and pigs: a pilot study. Schweizer Archiv für Tierheilkunde, 148(7), 341-2, 344. Bern: Huber 10.1024/0036-7281.148.7.341
Botteron, C; Doherr, MG; Heim, D; Mumford, E; Seuberlich, T (2007). Diagnostic techniques for transmissible spongiform encephalopathies. In: Rome: Food and agriculture organization of the United Nations (FAO)
Heim, D; Mumford, L; Murray, N; Samon, M; Seuberlich, T (2007). Epidemiology, surveillance and risk assessment for transmissible spongiform encephalopathies. In: (-). Rome: Food and agriculture organization of the United Nations (FAO)
